{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:28:59Z","timestamp":1794086939173,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) is a therapy approved for cystic fibrosis (CF) that has given improved clinical outcomes in patients carrying the F508del mutation. There are few published data regarding ETI\u2019s effects on patients\u2019 quality of life (QoL). This study aims to (fill the data gap in current literature by assessing) evaluate the long-term effects of ETI on QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>A prospective observational study was conducted with thirty-seven severe patients that received ETI for compassionate use (group A), 184 received it for on-label use (group B). All carried one F508del mutation. Patients were assessed using the CFQ-R (Cystic Fibrosis Questionnaire-Revised). The evaluation time-points were pre-treatment (T0), and after 12 (T1) and 24 months (T2); group A was also assessed after 36 months (T3). Twenty-five patients completed 3 years of treatment and 65 patients completed 2 years of treatment, in groups A and B respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At T1, median values for almost all areas of CFQ-R statistically significant increased in group A, particularly Physical Functioning (+\u200925.0), Respiratory (+\u200922.2) and Health Perception (+\u200922.2).The Social Functioning area statistically significant increased at T2 (+\u20095.6). At T3, these improvements remained stable. At T1, all areas of CFQ-R statistically significant increased in group B, particularly the Health Perception (+\u200922,2) heading. At T2, these improvements remained stable. For both groups, the changes identified at the last follow-up showed no major differences by gender, age or genetic status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with ETI significantly improved patients\u2019 QoL in both groups at 12\u201324 months, these improvements remaining stable in patients tested at 36 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-025-00879-0","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:35:23Z","timestamp":1746509723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor\/Tezacaftor\/Ivacaftor treatment"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1189-1144","authenticated-orcid":false,"given":"Francesca","family":"Buniotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Tridello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"De Scolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Meneghelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Pintani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Perobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cipolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"4","key":"879_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","volume":"22","author":"A Lopez","year":"2023","unstructured":"Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL (2023) Exacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros 22(4):607\u2013614. https:\/\/doi.org\/10.1016\/j.jcf.2023.02.004","journal-title":"J Cyst Fibros"},{"issue":"19","key":"879_CR2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"P Middleton","year":"2019","unstructured":"Middleton P, Mall M, D\u0159ev\u00ednek P, Lands L, McKone E, Polineni D et al (2019) Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381(19):1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","journal-title":"N Engl J Med"},{"issue":"10212","key":"879_CR3","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"H Heijerman","year":"2019","unstructured":"Heijerman H, McKone E, Downey D, Braeckel E, Rowe S, Tullis E et al (2019) Efficacy and safety of the Elexacaftor\/tezacaftor\/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394(10212):1940\u20131948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet"},{"key":"879_CR4","doi-asserted-by":"publisher","unstructured":"Abbott J, Hart A, Havermans T, Matossian A, Goldbeck L, Barreto C et al (2011 Jun) Measuring health-related quality of life in clinical trials in cystic fibrosis. J Cyst Fibros 10(Suppl 2):S82\u2013S85. https:\/\/doi.org\/10.1016\/S1569-1993(11)60013-1","DOI":"10.1016\/S1569-1993(11)60013-1"},{"key":"879_CR5","volume-title":"The cystic fibrosis questionnaire (CFQ): user\u2019s manual","author":"AL Quittner","year":"2000","unstructured":"Quittner AL, Buu A, Watrous M et al (2000) The cystic fibrosis questionnaire (CFQ): user\u2019s manual. Cystic Fibrosis Foundation, Washington DC"},{"issue":"4","key":"879_CR6","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","volume":"128","author":"AL Quittner","year":"2005","unstructured":"Quittner AL, Buu A, Messer MA, Modi AC, Watrous M (2005) Development and validation of the cystic fibrosis questionnaire in the united States: a health-related quality-of-life measure for cystic fibrosis. Chest 128(4):2347\u20132354. https:\/\/doi.org\/10.1378\/chest.128.4.2347","journal-title":"Chest"},{"issue":"1","key":"879_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","volume":"22","author":"I Fajac","year":"2023","unstructured":"Fajac I, Daines C, Durieu I, Goralski JL, Heijerman H, Knoop C et al (2023) Non-respiratory health-related quality of life in people with cystic fibrosis receiving Elexacaftor\/tezacaftor\/ivacaftor. J Cyst Fibros 22(1):119\u2013123. https:\/\/doi.org\/10.1016\/j.jcf.2022.08.018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"879_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/alr.22700","volume":"11","author":"E DiMango","year":"2021","unstructured":"DiMango E, Spielman DB, Overdevest J, Keating C, Fracasso FS, Dansky D et al (2021) Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis. Int Forum Allergy Rhinol 11(1):75\u201378. https:\/\/doi.org\/10.1002\/alr.22700","journal-title":"Int Forum Allergy Rhinol"},{"issue":"9","key":"879_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.arbres.2023.05.017","volume":"59","author":"L Carrasco Hern\u00e1ndez","year":"2023","unstructured":"Carrasco Hern\u00e1ndez L, Gir\u00f3n Moreno RM, Balaguer Cartagena MN, Pel\u00e1ez A, Sole A, \u00c1lvarez Fern\u00e1ndez A et al (2023) Experience with Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis and advanced disease. Arch Bronconeumol 59(9):556\u2013565. https:\/\/doi.org\/10.1016\/j.arbres.2023.05.017","journal-title":"Arch Bronconeumol"},{"key":"879_CR10","unstructured":"Nobili MV, Oprandi NC, Apolone G, Braggion C, Colombo C (2009) The Cystic Fibrosis Questionnaire CFQ-R Manuale d\u2019uso"},{"issue":"6","key":"879_CR11","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1378\/chest.08-1190","volume":"135","author":"AL Quittner","year":"2009","unstructured":"Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB (2009) Determination of the minimal clinically important difference scores for the cystic fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic pseudomonas aeruginosa airway infection. Chest 135(6):1610\u20131618. https:\/\/doi.org\/10.1378\/chest.08-1190","journal-title":"Chest"},{"issue":"21","key":"879_CR12","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.3390\/healthcare11212873","volume":"11","author":"W Gruber","year":"2023","unstructured":"Gruber W, Welsner M, Blosch C, Dillenhoefer S, Olivier M, Brinkmann F et al (2023) Long-Term Follow-Up of Health-Related quality of life and Short-Term intervention with CFTR modulator therapy in adults with cystic fibrosis: evaluation of changes over several years with or without 33 weeks of CFTR modulator therapy. Healthcare 11(21):2873. https:\/\/doi.org\/10.3390\/healthcare11212873","journal-title":"Healthcare"},{"key":"879_CR13","doi-asserted-by":"publisher","unstructured":"Mainz JG, Zagoya C, Polte L et al Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic Fibrosis-Early results obtained with the CF-Specific CFAbd-Score. Front Pharmacol 2022 Jun 3:13877118. https:\/\/doi.org\/10.3389\/fphar.2022.877118","DOI":"10.3389\/fphar.2022.877118"},{"issue":"2","key":"879_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","volume":"22","author":"SJ Schwarzenberg","year":"2023","unstructured":"Schwarzenberg SJ, Vu PT, Skalland M et al (2023) Elexacaftor\/tezacaftor\/ivacaftor and Gastrointestinal outcomes in cystic fibrosis: report of promise-GI. J Cyst Fibros 22(2):282\u2013289. https:\/\/doi.org\/10.1016\/j.jcf.2022.10.003","journal-title":"J Cyst Fibros"},{"key":"879_CR15","doi-asserted-by":"publisher","unstructured":"Calthorpe RJ, Goodchild N, Gleetus V et al A grumbling concern: an international survey of Gastrointestinal symptoms in cystic fibrosis in the modulator era. NIHR Open Res 2023 Apr 14:318. https:\/\/doi.org\/10.3310\/nihropenres.13384.1","DOI":"10.3310\/nihropenres.13384.1"},{"issue":"22","key":"879_CR16","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJM199011293232203","volume":"323","author":"E Kerem","year":"1990","unstructured":"Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison et al (1990) The relation between genotype and phenotype in cystic fibrosis analysis of the most common mutation (delta F508). N Engl J Med 323(22):1517\u20131522. https:\/\/doi.org\/10.1056\/NEJM199011293232203","journal-title":"N Engl J Med"},{"issue":"8742","key":"879_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/0140-6736(91)92449-c","volume":"337","author":"HK Johansen","year":"1991","unstructured":"Johansen HK, Nir M, H\u00f8iby N, Koch C, Schwartz M (1991) Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet 337(8742):631\u2013634. https:\/\/doi.org\/10.1016\/0140-6736(91)92449-c","journal-title":"Lancet"},{"issue":"2","key":"879_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jpsychores.2010.06.005","volume":"70","author":"GS Sawicki","year":"2011","unstructured":"Sawicki GS, Sellers DE, Robinson WM (2011) Associations between illness perceptions and health-related quality of life in adults with cystic fibrosis. J Psychosom Res 70(2):161\u2013167. https:\/\/doi.org\/10.1016\/j.jpsychores.2010.06.005","journal-title":"J Psychosom Res"},{"issue":"6","key":"879_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1023\/a:1005532602084","volume":"23","author":"J Abbott","year":"2000","unstructured":"Abbott J, Conway S, Etherington C, Fitzjohn J, Gee L, Morton A, Musson H, Webb AK (2000) Perceived body image and eating behavior in young adults with cystic fibrosis and their healthy peers. J Behav Med 23(6):501\u2013517. https:\/\/doi.org\/10.1023\/a:1005532602084","journal-title":"J Behav Med"},{"issue":"7","key":"879_CR20","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s11136-011-0091-5","volume":"21","author":"AL Quittner","year":"2012","unstructured":"Quittner AL, Sawicki GS, McMullen A et al (2012) Erratum to: psychometric evaluation of the cystic fibrosis Questionnaire-Revised in a National, US sample. Qual Life Res 21(7):1279\u20131290. https:\/\/doi.org\/10.1007\/s11136-011-0091-5","journal-title":"Qual Life Res"},{"issue":"1","key":"879_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/ppul.21325","volume":"46","author":"GS Sawicki","year":"2011","unstructured":"Sawicki GS, Rasouliyan L, McMullen AH, Wagener JS, McColley SA, Pasta DJ, Quittner AL (2011) Longitudinal assessment of Health-Related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol 46(1):36\u201344. https:\/\/doi.org\/10.1002\/ppul.21325","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"879_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1378\/chest.12-1404","volume":"144","author":"EJ Dill","year":"2013","unstructured":"Dill EJ, Dawson R, Sellers DE, Robinson WM, Sawicki GS (2013) Longitudinal trends in health-related quality of life in adults with cystic fibrosis. Chest 144(3):981\u2013989. https:\/\/doi.org\/10.1378\/chest.12-1404","journal-title":"Chest"},{"key":"879_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/03009734.2016.1225871","volume":"122","author":"J Hochw\u00e4lder","year":"2017","unstructured":"Hochw\u00e4lder J, Bergsten Brucefors A, Hjelte L (2017) Psychometric evaluation of the Swedish translation of the revised cystic fibrosis questionnaire in adults. Ups. J Med Sci 122:1: 61\u201366. https:\/\/doi.org\/10.1080\/03009734.2016.1225871","journal-title":"J Med Sci"},{"issue":"1","key":"879_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12890-022-01825-2","volume":"22","author":"A Page","year":"2022","unstructured":"Page A, Goldenberg A, Matthews A (2022) Lived experiences of individuals with cystic fibrosis on CFTR-modulators. BMC Pulm Med 22(1):42. https:\/\/doi.org\/10.1186\/s12890-022-01825-2","journal-title":"BMC Pulm Med"}],"updated-by":[{"DOI":"10.1186\/s41687-025-00976-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000}}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00879-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00879-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00879-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:54:22Z","timestamp":1781610862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-025-00879-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00879-0","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Article updated to correct the author names","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s41687-025-00976-0","URL":"https:\/\/doi.org\/10.1186\/s41687-025-00976-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the regional Ethics Committee of Regione Veneto (N. 36003 study group A; N. 2858CESC study group B). All patients (or parents of minors) were informed of the study\u2019s aims and procedures, and their written informed consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable because data has been anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}